FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2607263910> ?p ?o ?g. }

• W2607263910 endingPage "1949.e8" @default.
• W2607263910 startingPage "1940" @default.
• W2607263910 abstract "Silymarin is a complex mixture of 6 major flavonolignans and other minor polyphenolic compounds derived from the milk thistle plant Silybum marianum; it has shown antioxidant, anti-inflammatory and antifibrotic effects, and may be useful in patients with nonalcoholic fatty liver disease (NAFLD). We aimed to study the efficacy of silymarin in patients with nonalcoholic steatohepatitis (NASH)-the more severe form of NAFLD.We performed a randomized, double-blind, placebo-controlled trial of consecutive adults with biopsy-proven NASH and a NAFLD activity score (NAS) of 4 or more at a tertiary care hospital in Kuala Lumpur, Malaysia, from November 2012 through August 2014. Patients were randomly assigned to groups given silymarin (700 mg; n = 49 patients) or placebo (n = 50 patients) 3 times daily for 48 weeks. After this 48-week period, liver biopsies were repeated. The primary efficacy outcome was a decrease of 30% or more in NAS; findings from 48-week liver biopsies were compared with those from the baseline biopsy. Secondary outcomes included changes in steatosis, lobular inflammation, hepatocyte ballooning, NAS and fibrosis score, and anthropometric measurements, as well as glycemic, lipid, and liver profiles and liver stiffness measurements.The percentage of patients achieving the primary efficacy outcome did not differ significantly between the groups (32.7% in the silymarin group vs 26.0% in the placebo group; P = .467). A significantly higher proportion of patients in the silymarin group had reductions in fibrosis based on histology (reductions of 1 point or more; 22.4%) than did the placebo group (6.0%; P = .023), and based on liver stiffness measurements (decrease of 30% or more; 24.2%) than did the placebo group (2.3%; P = .002). The silymarin group also had significant reductions in mean aspartate aminotransferase to platelet ratio index (reduction of 0.14, P = .011 compared with baseline), fibrosis-4 score (reduction of 0.20, P = .041 compared with baseline), and NAFLD fibrosis score (reduction of 0.30, P < .001 compared with baseline); these changes were not observed in the placebo group (reduction of 0.07, P = .154; increase of 0.18, P = .389; and reduction of 0.05, P = .845, respectively). There was no significant difference between groups in number of adverse events; adverse events that occurred were not attributed to silymarin.In a randomized trial of 99 patients, we found that silymarin (700 mg, given 3 times daily for 48 weeks) did not reduce NAS scores by 30% or more in a significantly larger proportion of patients with NASH than placebo. Silymarin may reduce liver fibrosis but this remains to be confirmed in a larger trial. It appears to be safe and well tolerated. ClinicalTrials.gov: NCT02006498." @default.
• W2607263910 created "2017-04-28" @default.
• W2607263910 creator A5009827814 @default.
• W2607263910 creator A5077981491 @default.
• W2607263910 creator A5086873345 @default.
• W2607263910 date "2017-12-01" @default.
• W2607263910 modified "2023-10-10" @default.
• W2607263910 title "A Randomized Trial of Silymarin for the Treatment of Nonalcoholic Steatohepatitis" @default.
• W2607263910 cites W1898727195 @default.
• W2607263910 cites W1963683487 @default.
• W2607263910 cites W1965729726 @default.
• W2607263910 cites W1966166986 @default.
• W2607263910 cites W1980245616 @default.
• W2607263910 cites W1980992924 @default.
• W2607263910 cites W1987248421 @default.
• W2607263910 cites W1990964410 @default.
• W2607263910 cites W1995656733 @default.
• W2607263910 cites W1997425045 @default.
• W2607263910 cites W2000946002 @default.
• W2607263910 cites W2003227142 @default.
• W2607263910 cites W2025106732 @default.
• W2607263910 cites W2032846344 @default.
• W2607263910 cites W2036698572 @default.
• W2607263910 cites W2053309618 @default.
• W2607263910 cites W2059020006 @default.
• W2607263910 cites W2062812115 @default.
• W2607263910 cites W2064459152 @default.
• W2607263910 cites W2067740038 @default.
• W2607263910 cites W2073159020 @default.
• W2607263910 cites W2074203821 @default.
• W2607263910 cites W2075272295 @default.
• W2607263910 cites W2091106363 @default.
• W2607263910 cites W2100780314 @default.
• W2607263910 cites W2106768039 @default.
• W2607263910 cites W2107732097 @default.
• W2607263910 cites W2116393673 @default.
• W2607263910 cites W2117701880 @default.
• W2607263910 cites W2153068313 @default.
• W2607263910 cites W2156312046 @default.
• W2607263910 cites W2253420963 @default.
• W2607263910 cites W2524940154 @default.
• W2607263910 cites W4211191129 @default.
• W2607263910 doi "https://doi.org/10.1016/j.cgh.2017.04.016" @default.
• W2607263910 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28419855" @default.
• W2607263910 hasPublicationYear "2017" @default.
• W2607263910 type Work @default.
• W2607263910 sameAs 2607263910 @default.
• W2607263910 citedByCount "130" @default.
• W2607263910 countsByYear W26072639102017 @default.
• W2607263910 countsByYear W26072639102018 @default.
• W2607263910 countsByYear W26072639102019 @default.
• W2607263910 countsByYear W26072639102020 @default.
• W2607263910 countsByYear W26072639102021 @default.
• W2607263910 countsByYear W26072639102022 @default.
• W2607263910 countsByYear W26072639102023 @default.
• W2607263910 crossrefType "journal-article" @default.
• W2607263910 hasAuthorship W2607263910A5009827814 @default.
• W2607263910 hasAuthorship W2607263910A5077981491 @default.
• W2607263910 hasAuthorship W2607263910A5086873345 @default.
• W2607263910 hasConcept C126322002 @default.
• W2607263910 hasConcept C142724271 @default.
• W2607263910 hasConcept C168563851 @default.
• W2607263910 hasConcept C204787440 @default.
• W2607263910 hasConcept C27081682 @default.
• W2607263910 hasConcept C2775934546 @default.
• W2607263910 hasConcept C2776175330 @default.
• W2607263910 hasConcept C2776954865 @default.
• W2607263910 hasConcept C2777766500 @default.
• W2607263910 hasConcept C2778772119 @default.
• W2607263910 hasConcept C2779134260 @default.
• W2607263910 hasConcept C2909423643 @default.
• W2607263910 hasConcept C556039675 @default.
• W2607263910 hasConcept C71924100 @default.
• W2607263910 hasConcept C90924648 @default.
• W2607263910 hasConceptScore W2607263910C126322002 @default.
• W2607263910 hasConceptScore W2607263910C142724271 @default.
• W2607263910 hasConceptScore W2607263910C168563851 @default.
• W2607263910 hasConceptScore W2607263910C204787440 @default.
• W2607263910 hasConceptScore W2607263910C27081682 @default.
• W2607263910 hasConceptScore W2607263910C2775934546 @default.
• W2607263910 hasConceptScore W2607263910C2776175330 @default.
• W2607263910 hasConceptScore W2607263910C2776954865 @default.
• W2607263910 hasConceptScore W2607263910C2777766500 @default.
• W2607263910 hasConceptScore W2607263910C2778772119 @default.
• W2607263910 hasConceptScore W2607263910C2779134260 @default.
• W2607263910 hasConceptScore W2607263910C2909423643 @default.
• W2607263910 hasConceptScore W2607263910C556039675 @default.
• W2607263910 hasConceptScore W2607263910C71924100 @default.
• W2607263910 hasConceptScore W2607263910C90924648 @default.
• W2607263910 hasIssue "12" @default.
• W2607263910 hasLocation W26072639101 @default.
• W2607263910 hasLocation W26072639102 @default.
• W2607263910 hasOpenAccess W2607263910 @default.
• W2607263910 hasPrimaryLocation W26072639101 @default.
• W2607263910 hasRelatedWork W2083336557 @default.
• W2607263910 hasRelatedWork W2093272464 @default.
• W2607263910 hasRelatedWork W2108480274 @default.
• W2607263910 hasRelatedWork W2110709791 @default.

• next